Curated News
By: NewsRamp Editorial Staff
May 13, 2025
NRx Pharmaceuticals Acquires Kadima Neuropsychiatry Institute for Interventional Psychiatry Treatments
TLDR
- Acquiring Kadima Neuropsychiatry Institute, NRx Pharmaceuticals gains a leading edge in interventional psychiatry treatments, setting a new standard.
- NRx Pharmaceuticals' subsidiary HOPE Therapeutics signed an agreement to acquire Kadima for its advanced treatments and profitable clinical model.
- Through the acquisition of Kadima Neuropsychiatry Institute, NRx Pharmaceuticals aims to improve mental health care, offering hope and innovative solutions.
- Kadima Neuropsychiatry Institute provides cutting-edge treatments like ketamine and TMS, revolutionizing mental health care with personalized approaches and new technologies.
Impact - Why it Matters
This news matters because the acquisition of Kadima by NRx Pharmaceuticals signifies a strategic move to expand its offerings in treating CNS disorders. With Kadima's expertise in interventional psychiatry, NRx is positioning itself as a leader in providing innovative treatments for conditions such as suicidal depression and PTSD.
Summary
NRx Pharmaceuticals (NASDAQ: NRXP) announced the acquisition of the Kadima Neuropsychiatry Institute by its subsidiary, HOPE Therapeutics. Kadima specializes in interventional psychiatry treatments for CNS disorders including suicidal depression and PTSD. Dr. David Feifel, Kadima's founder, will join HOPE as Chief Medical Innovation Officer.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NRx Pharmaceuticals Acquires Kadima Neuropsychiatry Institute for Interventional Psychiatry Treatments
